{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mei Z"],"funding":["Research Project of Jinan Microecological Biomedicine Shandong Laboratory","Unit Project of Chinese Academy of Medical Science","the Health Commission of Zhejiang Province"],"pagination":["1284-1296"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10067412"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["114(4)"],"pubmed_abstract":["Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1<sup>+</sup> CD8<sup>+</sup> T cells in HCC microenvironment have not been systematically studied. Here, we established an orthotopic hepa1-6 mouse model treated with lenvatinib to investigate CD8<sup>+</sup> T cells' role in the tumor and spleen. We found an increasing proportion of TCF-1<sup>+</sup> in PD1<sup>+</sup> CD8<sup>+</sup> T cells and proliferation of PD1<sup>+</sup> CD8<sup>+</sup> T cells after lenvatinib treatment. Meanwhile, lenvatinib treatment upregulated the expression of granzyme B on PD1<sup>+</sup> CD8<sup>+</sup> T cells both in vitro and in vivo. Lenvatinib activated the endoge"],"journal":["Cancer science"],"pubmed_title":["Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1<sup>+</sup> CD8<sup>+</sup> T cells in HCC via blocking VEGFR2."],"pmcid":["PMC10067412"],"funding_grant_id":["JBZX-202004","JNL-2022008B","2019-I2M-5-030","JNL-2022002A"],"pubmed_authors":["Xu K","Zhou L","Qian J","Pan C","Wu Q","Wang S","Mei Z","Zhen S","Gao X","Xu Z"],"additional_accession":[]},"is_claimable":false,"name":"Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1<sup>+</sup> CD8<sup>+</sup> T cells in HCC via blocking VEGFR2.","description":"Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1<sup>+</sup> CD8<sup>+</sup> T cells in HCC microenvironment have not been systematically studied. Here, we established an orthotopic hepa1-6 mouse model treated with lenvatinib to investigate CD8<sup>+</sup> T cells' role in the tumor and spleen. We found an increasing proportion of TCF-1<sup>+</sup> in PD1<sup>+</sup> CD8<sup>+</sup> T cells and proliferation of PD1<sup>+</sup> CD8<sup>+</sup> T cells after lenvatinib treatment. Meanwhile, lenvatinib treatment upregulated the expression of granzyme B on PD1<sup>+</sup> CD8<sup>+</sup> T cells both in vitro and in vivo. Lenvatinib activated the endoge","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-04T10:42:35.637Z","creation":"2025-04-04T10:42:35.637Z"},"accession":"S-EPMC10067412","cross_references":{"pubmed":["36609997"],"doi":["10.1111/cas.15719"]}}